Cannabis
Mycrodose Therapeutics to Discuss Advanced Drug Delivery Devices at Psychedelic Medicine Event
San Diego, California–(Newsfile Corp. – July 27, 2021) – Mycrodose Therapeutics, a US-Based pharmaceutical company focused on developing advanced drug delivery systems for use with psychedelic compounds, announced today that its Executive team will be participating in the upcoming Psychedelic Capital Event on July 29, 2021.
The virtual conference hosted by Microdose Psychedelic Insights will enable Mycrodose Therapeutics the opportunity to present as a panel on the company’s core drug delivery systems, their major milestones & accomplishments, and the company’s outlook on the expanding psychedelic pharmaceutical sector.
“Mycrodose Therapeutics started from a deep personal need to find better solutions for treating mental health. We have a deep desire of improving the fight against the mental health pandemic that impacts all ages, all ethnicities, all genders, and spans the entire globe. Our continued mission is to develop cutting-edge technologies and novel IP in order to bring more happiness, love, connection, and understanding to those suffering. We look forward to sharing more at the Psychedelic Capital Event this week.” – Patrick Eckstrom, Chief Operating Officer.
Panel Topic: Advanced Drug Delivery of Psychedelic Compounds
Panel Presenters: Chad Conner, Chief Executive Officer; Frank Kochinke, Chief Science Officer; Patrick Eckstrom, Chief Operating Officer
Date: Thursday, July 29, 2021
Time: 10:30 AM PST (1:30 PM EST) – Introduction by Patrick Moher, CEO of Microdose Psychedelic Insights, and Richard Skaife, Co-Founder of The Conscious Fund.
10:45 AM PST (1:45 PM EST) – Presentation by Mycrodose Therapeutics
Tickets: FREE Only Through This Link: https://microdose.buzz/discount/psycap/
About Mycrodose Therapeutics
Mycrodose Therapeutics is a US-Based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. Mycrodose is one of only a few private companies that has been granted a Schedule I License to research four (4) psychedelic compounds: Psilocybin, MDMA, DMT & LSD by the United States Drug Enforcement Agency (DEA).
For more information about Mycrodose Therapeutics, please contact:
Patrick Eckstrom
Chief Operating Officer
Mycrodose Therapeutics
Email: [email protected]
Phone: 1-619-494-1367
Website: www.MycrodoseThera.com
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
Cannabis
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
Cannabis
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Cannabis2 weeks ago
Right On Brands, Inc. Continues Rollout, Announces 13th Store Opening
-
Cannabis2 weeks ago
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
-
Cannabis2 weeks ago
Geopulse Exploration, Inc. Acquires 50% of ATC Services
-
transfer1 week ago
IMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis1 week ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
Cannabis6 days ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Cannabis5 days ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
CCELL®1 week ago
CCELL Launches Environmentally Conscious Eco Star AIO Vaporizer